David O'Malley, MD

Articles

Trastuzumab in Endometrial Carcinoma Therapy

March 24th 2022

Dr David O’Malley explains when to add and remove trastuzumab during endometrial carcinoma therapy.

I/O + Chemotherapy Treatments for Endometrial Carcinoma

March 18th 2022

A review of data from several clinical trials on the use of I/O + chemotherapy as treatment for endometrial carcinoma.

Biomarker Testing in Endometrial Carcinoma

March 4th 2022

An overview of biomarker testing in endometrial carcinoma.

Dr. O’Malley on the Rationale to Evaluate Balstilimab/Zalifrelimab in Cervical Cancer

October 6th 2021

David M. O'Malley, MD, discusses the rationale to evaluate the combination of balstilimab and zalifrelimab in cervical cancer.

Dr. O’Malley on Balstilimab and Zalifrelimab in Recurrent/Metastatic Cervical Cancer

September 24th 2021

David M. O'Malley, MD, discusses future research directions with balstilimab and zalifrelimab in patients with cervical cancer.

Dr. O’Malley on the Promise of Antibody-Drug Conjugates in Ovarian Cancer

July 14th 2021

David M. O'Malley, MD, discusses the promise of antibody-drug conjugates in ovarian cancer.

Dr. O’Malley on the Results of the KEYNOTE-775 Trial in Endometrial Cancer

April 15th 2021

David M. O'Malley, MD, discusses the results of the phase 3 KEYNOTE-775 trial in advanced endometrial cancer.

Dr. O’Malley on the Safety Profile of Mirvetuximab in Ovarian Cancer

September 3rd 2020

David O'Malley, MD, discusses the adverse effects associated with mirvetuximab soravtansine in ovarian cancer.

Dr. O’Malley on the Activity of Mirvetuximab Soravtansine in Ovarian Cancer

July 21st 2020

David O'Malley, MD, discusses the activity of the investigational antibody-drug conjugate mirvetuximab soravtansine in ovarian cancer.

Dr. O’Malley on the Utility of Mirvetuximab in Ovarian Cancer

June 24th 2020

David O'Malley, MD, discusses the utility of mirvetuximab soravtansine in ovarian cancer.

Dr. O'Malley on Antitumor Activity With Veliparib Combo in Serous Ovarian Cancer

April 22nd 2020

David O'Malley, MD, discusses antitumor activity with veliparib in combination with chemotherapy in patients with high grade serous ovarian cancer.

Dr. O'Malley on Increased Benefit of Rucaparib Maintenance in RAD51C/D-Mutant Ovarian Cancer

April 10th 2020

David O'Malley, MD, discusses the increased benefit of rucaparib maintenance in patients with ovarian cancer who express RAD51C/D mutations.

Dr. O'Malley on Maintenance Rucaparib in Non-BRCA HRR-Mutated Ovarian Cancer

April 9th 2020

David O’Malley, MD, discusses the rationale to evaluate the clinical benefit of rucaparib maintenance treatment following disease progression in a subgroup of patients with ovarian cancer whose disease is associated with a mutation in a non-BRCA homologous recombination gene in the phase III ARIEL3 trial in ovarian cancer.

Dr. O'Malley on Research With Immunotherapy in Ovarian Cancer

April 8th 2020

David O’Malley, MD, discusses the current state of immunotherapy in ovarian cancer.

Dr. O'Malley on the State of Immunotherapy in Ovarian Cancer

March 26th 2020

David O’Malley, MD, discusses the state of immunotherapy in ovarian cancer.

Dr. O'Malley on the Optimal Use of PARP Inhibitors in Advanced Ovarian Cancer

March 10th 2020

David O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, and director, Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–The James, discusses the optimal use of PARP inhibitors as frontline maintenance therapy in patients with advanced ovarian cancer.

Dr. O'Malley on Remaining Questions in Ovarian Cancer

January 8th 2020

David O’Malley, MD, discusses remaining questions in the ovarian cancer field.

Dr. O'Malley on Ongoing Clinical Trials Evaluating Immunotherapy in Ovarian Cancer

December 19th 2019

David O’Malley, MD, discusses ongoing clinical trials evaluating immunotherapy in patients with advanced ovarian cancer.

Dr. O'Malley on Toxicity Profiles of PARP Inhibitors in Ovarian Cancer

November 5th 2019

David O’Malley, MD, discusses the toxicities associated with PARP inhibitors in ovarian cancer.

Dr. O'Malley on Folate-Receptor Alpha as a Biomarker in Ovarian Cancer

August 10th 2018

David O'Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, discusses folate-receptor alpha as a biomarker in ovarian cancer.